Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. More »

Featured News

Recent News

01/03/19GBT Announces New Employment Inducement Grants
01/02/19GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
12/21/18GBT Appoints Dawn Svoronos to Board of Directors
12/07/18Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering

More »

Media Resources

Stay Informed

Sign up to receive email updates about ongoing sickle cell disease clinical studies, awareness and educational information and GBT news at:

Media Contact

Stephanie Yao